MedVax Technologies, Inc. CEO to attend BIO CEO & Investor Conference 2015
MIAMI, FL - February 9, 2015 - MedVax Technologies, Inc., a pharmaceutical company developing and commercialization cancer vaccines, announced today Robert K. Brooks, Chief Executive Officer, will attend the 17th Annual BIO CEO & Investor Conference to be held February 9 - 10 at The Waldorf Astoria New York.
BIO CEO & Investor Conference
The annual BIO CEO & Investor Conference attracts hundreds of executives and investors in the biotechnology industry. The conference is one of the largest gatherings spotlighting hundreds of publicly traded and private biotech companies.
The event features company presentations, educational seminars and the opportunity for one-on-one meetings, executive roundtables, and other networking sessions.
BIO is the largest trade association in the world. It represents biotechnology companies, state biotechnology centers, and educational institutions in more than 30 nations. BIO also produces the BIO International Convention, the largest gathering of the biotechnology industry in the world.
About MedVax Technologies, Inc.
MedVax is a biopharmaceutical company discovering and commercializing cancer vaccines. MedVax's portfolio includes: MX-402, a unique B-cell epitope HER-2 Peptide vaccine that had showed strong signals of efficacy in an interim Phase I trial, 8 of 12 patients showed clinical benefit, with one patient in complete remission; and, MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer, and recruiting in breast cancer. Medvax's team is comprised of world renowned scientists and biotech industry professionals.
Cautionary Note on Forward-Looking Statements:
This press release and any statements of representatives and partners of MedVax Technologies, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
MedVax Technologies, Inc.
VP, Business Administration & Public Relations
One Mifflin Place, Ste. 400
Cambridge, MA 02138
Tel: (617) 674-7718
Fax: (617) 674-7701
25 SE 2nd Avenue, Ste. 504
Miami, FL 33131
Tel: (305) 371-2301
Fax: (305) 371-2304
Source: MedVax Technologies, Inc.